In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Synthetic biology company Intrexon acquires protein therapeutics company ActoGeniX

Executive Summary

Intrexon Corp. (synthetic biology) acquired ActoGeniX NV (protein therapies) for approximately $30mm in cash plus $30mm in stock (via the issuance of 965k shares). The transaction is expected to close in Q1 2015.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies

UsernamePublicRestriction

Register